Literature DB >> 29959132

Prostate Cancer Epigenetics: From Basic Mechanisms to Clinical Implications.

Srinivasan Yegnasubramanian1, Angelo M De Marzo1, William G Nelson1.   

Abstract

A level of epigenetic programming, encoded by complex sets of chemical marks on DNA and histones, and by context-specific DNA, RNA, protein interactions, that all regulate the structure, organization, and function of the genome, is critical to establish both normal and neoplastic cell identities and functions. This structure-function relationship of the genome encoded by the epigenetic programming can be thought of as an epigenetic cityscape that is built on the underlying genetic landscape. Alterations in the epigenetic cityscape of prostate cancer cells compared with normal prostate tissues have a complex interplay with genetic alterations to drive prostate cancer initiation and progression. Indeed, mutations in genes encoding epigenetic enzymes are often observed in human cancers including prostate cancer. Interestingly, alterations in the prostate cancer epigenetic cityscape can be highly recurrent, a facet that can be exploited for development of biomarkers and potentially as therapeutic targets.
Copyright © 2019 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 29959132      PMCID: PMC6444700          DOI: 10.1101/cshperspect.a030445

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  144 in total

Review 1.  ATRX and DAXX: Mechanisms and Mutations.

Authors:  Michael A Dyer; Zulekha A Qadeer; David Valle-Garcia; Emily Bernstein
Journal:  Cold Spring Harb Perspect Med       Date:  2017-03-01       Impact factor: 6.915

2.  Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study.

Authors:  Grant D Stewart; Leander Van Neste; Philippe Delvenne; Paul Delrée; Agnès Delga; S Alan McNeill; Marie O'Donnell; James Clark; Wim Van Criekinge; Joseph Bigley; David J Harrison
Journal:  J Urol       Date:  2012-10-08       Impact factor: 7.450

Review 3.  Chromatin modifiers and remodellers: regulators of cellular differentiation.

Authors:  Taiping Chen; Sharon Y R Dent
Journal:  Nat Rev Genet       Date:  2013-12-24       Impact factor: 53.242

4.  CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer.

Authors:  Patrick J Bastian; Ganesh S Palapattu; Srinivasan Yegnasubramanian; Craig G Rogers; Xiaohui Lin; Leslie A Mangold; Bruce Trock; Mario A Eisenberger; Alan W Partin; William G Nelson
Journal:  J Urol       Date:  2008-02       Impact factor: 7.450

5.  MeCP2 binds to 5hmC enriched within active genes and accessible chromatin in the nervous system.

Authors:  Marian Mellén; Pinar Ayata; Scott Dewell; Skirmantas Kriaucionis; Nathaniel Heintz
Journal:  Cell       Date:  2012-12-21       Impact factor: 41.582

6.  Recognition of hemi-methylated DNA by the SRA protein UHRF1 by a base-flipping mechanism.

Authors:  Kyohei Arita; Mariko Ariyoshi; Hidehito Tochio; Yusuke Nakamura; Masahiro Shirakawa
Journal:  Nature       Date:  2008-09-03       Impact factor: 49.962

7.  DNA methylation presents distinct binding sites for human transcription factors.

Authors:  Shaohui Hu; Jun Wan; Yijing Su; Qifeng Song; Yaxue Zeng; Ha Nam Nguyen; Jaehoon Shin; Eric Cox; Hee Sool Rho; Crystal Woodard; Shuli Xia; Shuang Liu; Huibin Lyu; Guo-Li Ming; Herschel Wade; Hongjun Song; Jiang Qian; Heng Zhu
Journal:  Elife       Date:  2013-09-03       Impact factor: 8.140

8.  Increased methylation variation in epigenetic domains across cancer types.

Authors:  Kasper Daniel Hansen; Winston Timp; Héctor Corrada Bravo; Sarven Sabunciyan; Benjamin Langmead; Oliver G McDonald; Bo Wen; Hao Wu; Yun Liu; Dinh Diep; Eirikur Briem; Kun Zhang; Rafael A Irizarry; Andrew P Feinberg
Journal:  Nat Genet       Date:  2011-06-26       Impact factor: 38.330

9.  A DNA hypermethylation module for the stem/progenitor cell signature of cancer.

Authors:  Hariharan Easwaran; Sarah E Johnstone; Leander Van Neste; Joyce Ohm; Tim Mosbruger; Qiuju Wang; Martin J Aryee; Patrick Joyce; Nita Ahuja; Dan Weisenberger; Eric Collisson; Jingchun Zhu; Srinivasan Yegnasubramanian; William Matsui; Stephen B Baylin
Journal:  Genome Res       Date:  2012-03-05       Impact factor: 9.043

10.  The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain.

Authors:  Skirmantas Kriaucionis; Nathaniel Heintz
Journal:  Science       Date:  2009-04-16       Impact factor: 47.728

View more
  12 in total

Review 1.  Genomic and phenotypic heterogeneity in prostate cancer.

Authors:  Michael C Haffner; Wilbert Zwart; Martine P Roudier; Lawrence D True; William G Nelson; Jonathan I Epstein; Angelo M De Marzo; Peter S Nelson; Srinivasan Yegnasubramanian
Journal:  Nat Rev Urol       Date:  2020-12-16       Impact factor: 14.432

2.  Epigenetic Coregulation of Androgen Receptor Signaling.

Authors:  Rayzel C Fernandes; Damien A Leach; Charlotte L Bevan
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

Review 3.  The tubal epigenome - An emerging target for ovarian cancer.

Authors:  Hunter D Reavis; Ronny Drapkin
Journal:  Pharmacol Ther       Date:  2020-03-18       Impact factor: 12.310

4.  GSTP1 positive prostatic adenocarcinomas are more common in Black than White men in the United States.

Authors:  Igor Vidal; Qizhi Zheng; Jessica L Hicks; Jiayu Chen; Elizabeth A Platz; Bruce J Trock; Ibrahim Kulac; Javier A Baena-Del Valle; Karen S Sfanos; Sarah Ernst; Tracy Jones; Janielle P Maynard; Stephanie A Glavaris; William G Nelson; Srinivasan Yegnasubramanian; Angelo M De Marzo
Journal:  PLoS One       Date:  2021-06-30       Impact factor: 3.240

5.  Random forest-based modelling to detect biomarkers for prostate cancer progression.

Authors:  Reka Toth; Heiko Schiffmann; Claudia Hube-Magg; Franziska Büscheck; Doris Höflmayer; Sören Weidemann; Patrick Lebok; Christoph Fraune; Sarah Minner; Thorsten Schlomm; Guido Sauter; Christoph Plass; Yassen Assenov; Ronald Simon; Jan Meiners; Clarissa Gerhäuser
Journal:  Clin Epigenetics       Date:  2019-10-22       Impact factor: 6.551

6.  SChLAP1 promotes prostate cancer development through interacting with EZH2 to mediate promoter methylation modification of multiple miRNAs of chromosome 5 with a DNMT3a-feedback loop.

Authors:  Kai Huang; Yuxin Tang
Journal:  Cell Death Dis       Date:  2021-02-15       Impact factor: 8.469

Review 7.  Lipid Metabolism and Epigenetics Crosstalk in Prostate Cancer.

Authors:  Juan C Pardo; Vicenç Ruiz de Porras; Joan Gil; Albert Font; Manel Puig-Domingo; Mireia Jordà
Journal:  Nutrients       Date:  2022-02-18       Impact factor: 5.717

Review 8.  The Etiology and Pathophysiology Genesis of Benign Prostatic Hyperplasia and Prostate Cancer: A New Perspective.

Authors:  Teow J Phua
Journal:  Medicines (Basel)       Date:  2021-06-11

Review 9.  Epigenetic Editing in Prostate Cancer: Challenges and Opportunities.

Authors:  Mariana Brütt Pacheco; Vânia Camilo; Rui Henrique; Carmen Jerónimo
Journal:  Epigenetics       Date:  2021-06-15       Impact factor: 4.861

10.  Aberrant SOCS3 Promoter Methylation as a Noninvasive Diagnostic Biomarker for Locally Advanced Prostate Cancer.

Authors:  Berna Demircan Tan; Turgay Turan; Burcu Yucel; Sedef Altundag Kara; Seda Salman Yilmaz; Asif Yildirim
Journal:  Medeni Med J       Date:  2020-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.